文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

贝达喹啉治疗耐多药结核病患者的结局

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
PubMed 文献 · Emerg Infect Dis · 2019-01-01

该研究汇总法国、格鲁吉亚、亚美尼亚、南非及多国研究中5个接受贝达喹啉治疗的队列数据,评估耐多药/广泛耐药结核患者的结局。6个月培养转阴率78%(95%CI 73.5%-81.9%),治疗成功率65.8%(95%CI 59.9%-71.3%),病死率11.7%(95%CI 7.0%-19.1%)。贝达喹啉方案在不同背景下有效且安全,但证据确定性极低。

要点

  • 贝达喹啉治疗6个月培养转阴率达78%。
  • 治疗成功率65.8%,病死率11.7%。
  • 肺空洞与不良结局持续相关。

核心结论

  • 贝达喹啉用于耐多药和广泛耐药结核治疗方案在不同背景下显示有效且安全,但证据确定性评估为极低。

研究设计与样本

  • 汇总法国、格鲁吉亚、亚美尼亚、南非及多国研究中5个接受贝达喹啉治疗的患者队列数据。

主要发现

  • 6个月(治疗6个月结束时)培养转阴率为78%(95%CI 73.5%-81.9%)。
  • 治疗成功率为65.8%(95%CI 59.9%-71.3%),病死率为11.7%(95%CI 7.0%-19.1%)。
  • 高达91.1%(95%CI 82.2%-95.8%)的患者经历至少1次不良事件,11.2%(95%CI 5.0%-23.2%)经历严重不良事件。
  • 肺空洞始终与不良结局相关。

临床怎么用

  • 在耐多药和广泛耐药结核治疗方案中可考虑使用贝达喹啉,但需注意证据确定性极低。
  • 治疗期间应监测不良事件,尤其严重不良事件。
  • 存在肺空洞的患者可能预后更差,需加强管理。

局限性

  • 证据确定性被评估为极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%-81.9%), and the treatment success rate was 65.8% (95% CI 59.9%-71.3%). Death rate was 11.7% (95% CI 7.0%-19.1%). Up to 91.1% (95% CI 82.2%-95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%-23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2019. PMID: 31002070. doi:10.3201/eid2505.181823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。